Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | ELANE | P08246 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2106301 | 0.86 | GAA (0.32) | GAAL3MBTL1HTTELANE | |
| SCHEMBL2104580 | 0.86 | GAA (0.32) | GAAL3MBTL1HTTELANE | |
| SCHEMBL14775157 | 0.84 | L3MBTL1 (0.34) | GAAL3MBTL1HTT | |
| Meparfynol Carbamate SCHEMBL1171789 | 0.83 | ALOX15 (0.34) | GAALMNAHSD17B10L3MBTL1 | |
| Meparfynol Carbamate SCHEMBL1171403 | 0.83 | ALOX15 (0.34) | GAALMNAHSD17B10L3MBTL1 | |
| SCHEMBL8846596 | 0.82 | ALDH1A1 (0.35) | GAAALDH1A1 | |
| SCHEMBL5557058 | 0.81 | L3MBTL1 (0.33) | L3MBTL1 | |
| SCHEMBL2106869 | 0.81 | L3MBTL1 (0.35) | L3MBTL1HTTELANE | |
| SCHEMBL28444038 | 0.81 | — | — | |
| SCHEMBL14107566 | 0.80 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11693163-B2 | Optical filter and imaging device | AGC Inc. (JP) | 2023-07-04 | — | — | US | disclosed |
| US-20180067243-A1 | OPTICAL FILTER AND IMAGING DEVICE | ASAHI GLASS COMPANY, LIMITED (JP) | 2018-03-08 | — | — | US | disclosed |
| EP-2369670-B1 | Non-aqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES (JP) | 2016-03-23 | — | — | EP | disclosed |
| US-8722255-B2 | Non-aqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES, LTD. (JP) | 2014-05-13 | — | — | US | disclosed |
| US-8530080-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2013-09-10 | — | — | US | disclosed |
| US-8440349-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2013-05-14 | — | — | US | disclosed |
| US-20130052541-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | UBE INDUSTRIES, LTD. (JP) | 2013-02-28 | — | — | US | disclosed |
| US-20120183864-A1 | NON-AQUEOUS ELECTROLYTIC SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY USING THE SAME | UBE INDUSTRIES, LTD. (JP) | 2012-07-19 | — | — | US | disclosed |
| US-8163427-B2 | Nonaqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES, LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2369670-A1 | Non-aqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | Ube Industries, Ltd. (JP) | 2011-09-28 | — | — | EP | disclosed |
| CN-100517853-C | Nonaqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES (JP) | 2009-07-22 | — | — | CN | disclosed |
| US-20090053598-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | MU IONIC SOLUTIONS CORPORATION (JP) | 2009-02-26 | — | — | US | disclosed |
| CN-101107745-A | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES (JP) | 2008-01-16 | — | — | CN | disclosed |
| CN-1853307-A | Nonaqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | UBE INDUSTRIES (JP) | 2006-10-25 | — | — | CN | disclosed |
| US-20060177742-A1 | Nonaqueous electrolytic solution for lithium secondary battery and lithium secondary battery using the same | MU IONIC SOLUTIONS CORPORATION (JP) | 2006-08-10 | — | — | US | disclosed |
| EP-1650826-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION FOR LITHIUM SECONDARY BATTERY AND LITHIUM SECONDARY BATTERY USING SAME | Ube Industries, Ltd. (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | LIGAND PHARMACEUTICALS, INC. | 2005-12-29 | — | — | US | disclosed |
| US-6964973-B2 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-11-15 | — | — | US | disclosed |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | LIGAND PHARMACEUTICALS, INC. | 2003-07-10 | — | — | US | disclosed |
| US-6566372-B1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer | LIGAND PHARMACEUTICALS INCORPORATED | 2003-05-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288350-A1 | Useful in female hormone replacement therapy and as modulators of fertility; therapy of dysfunctional uterine bleeding, dysmenorrhea, endometriosis, leiomyomas (uterine fibroids), hot flashes, mood disorders, meningiomas, cancer; 6-(bis-2,2,2-Trifluoroethyl)amino-4-trifluoromethylcoumarin | FSHR, CYP19A1, ESR2 | GAA 4885/4885ALDH1A1 2798/4885LMNA 1047/4885 |
| US-20030130505-A1 | Bicyclic androgen and progesterone receptor modulator compounds and methods | AR, NR5A1, PGR | GAA 4834/4885ALDH1A1 2131/4885LMNA 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.